Eli Lilly

API manufacturing facility in Huntsville, Alabama, for small-molecule synthetic and peptide medicines including the oral GLP-1 drug orforglipron. Announced December 9, 2025; expected to create 450 permanent manufacturing jobs and about 3,000 construction jobs. Construction expected to begin in 2026 with completion targeted for 2032.

Investment
$6.00B
Permanent jobs announced
450
Status
Planning
Expected opening
Jan 1, 2032
Why this project qualifies

With $6 billion in facility-specific investment and 450 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.

View full methodology →
Why it matters

The pharmaceuticals context.

Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.

Project record

At a glance

Company
Eli Lilly
Industry
Pharmaceuticals
Location
Huntsville, Alabama
Investment
$6.00B
Permanent jobs announced
450
Status
Planning
Announced
Dec 9, 2025
Expected opening
Jan 1, 2032
Added to tracker
Feb 11, 2026
Sources

Official references

  • Primary source
    https://investor.lilly.com/news-releases/news-release-details/lilly-build-6-billion-facility-manufacture-active-pharmaceutical
Related

Other projects to know

Back to the tracker/projects/eli-lilly-huntsville